Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21070375 | 1.00 | TDP1 (0.43) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL21070330 | 1.00 | TDP1 (0.43) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL21070586 | 1.00 | TDP1 (0.43) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL2799460 | 0.97 | TDP1 (0.45) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL21068476 | 0.92 | TDP1 (0.48) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL31615713 | 0.91 | CA12 (0.37) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL31615561 | 0.91 | CA12 (0.37) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL21068292 | 0.90 | CA12 (0.52) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL20696677 | 0.90 | TDP1 (0.42) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL23499716 | 0.88 | TDP1 (0.43) | TDP1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-12312316-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| EP-4509184-A2 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas Operations, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| US-20250034096-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2025-01-30 | — | — | US | disclosed |
| EP-3526202-B1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-01-02 | — | — | US | disclosed |
| US-12168057-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| CN-114174299-B | Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitors to E3 ligase ligand and methods of use | 百济神州有限公司 | 2024-10-25 | — | — | CN | disclosed |
| WO-2016118666-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR | Arvinas, Inc. (US) | 2016-07-28 | — | — | WO | disclosed |
| EP-1534334-B1 | RELEASABLE POLYMERIC CONJUGATES BASED ON ALIPHATIC BIODEGRADABLE LINKERS | BELROSE PHARMA INC (US) | 2014-06-25 | — | — | EP | disclosed |
| EP-2338513-A2 | Releasable polymeric conjugates based on aliphatic biodegradable linkers | ENZON, INC. (US) | 2011-06-29 | — | — | EP | disclosed |
| US-7897647-B2 | Useful in extending the in vivo circulating life of biologically active materials; bicine linker allows for the manipulation of the hydrolysis rate of the prodrug, thereby releasing the native entities at various rates in vivo as well as in vitro | ENZON PHARMACEUTICALS, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| EP-1534334-A4 | RELEASABLE POLYMERIC CONJUGATES BASED ON ALIPHATIC BIODEGRADABLE LINKERS | ENZON INC (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20060286065-A1 | Releasable polymeric conjugates based on aliphatic biodegradable linkers | BELROSE PHARMA INC. | 2006-12-21 | — | — | US | disclosed |
| US-7122189-B2 | Releasable polymeric conjugates based on aliphatic biodegradable linkers | ENZON, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1534334-A1 | RELEASABLE POLYMERIC CONJUGATES BASED ON ALIPHATIC BIODEGRADABLE LINKERS | ENZON, INC. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040037802-A1 | Releasable polymeric conjugates based on aliphatic biodegradable linkers | BELROSE PHARMA INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2004014424-A1 | RELEASABLE POLYMERIC CONJUGATES BASED ON ALIPHATIC BIODEGRADABLE LINKERS | ENZON, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TDP1 236/4885CA12 4583/4885CA1 4622/4885 |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TDP1 236/4885CA12 4583/4885CA1 4622/4885 |
| US-12312316-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, MDM2, ESRRA | TDP1 3660/4885CA12 2708/4885CA1 2519/4885 |
| US-20250034096-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | TDP1 2798/4885CA12 1893/4885CA1 828/4885 |
| US-20040037802-A1 | Releasable polymeric conjugates based on aliphatic biodegradable linkers | CD44, PAICS, PCBP1 | TDP1 955/4885CA12 2320/4885CA1 2667/4885 |
| US-12168057-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TDP1 236/4885CA12 4583/4885CA1 4622/4885 |
| US-20060286065-A1 | Releasable polymeric conjugates based on aliphatic biodegradable linkers | CD44, PAICS, PCBP1 | TDP1 1452/4885CA12 2126/4885CA1 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.